Retrospective Study
Copyright ©The Author(s) 2021.
World J Gastrointest Endosc. Jan 16, 2021; 13(1): 13-23
Published online Jan 16, 2021. doi: 10.4253/wjge.v13.i1.13
Table 3 Incremental Cost Effectiveness Ratio analysis
Efficacy outcome
ICER analysis
Early rebleeding (n of events)(USD 3048.50) - (USD 11060.90)/(0) - (3) = US$ 2670.80
Adverse events (n of events)(USD 3048.50) - (USD 11060.90)/(2) - (3) = US$ 8012.40
Length of hospitalization (total days)(USD 3048.50) - (USD 11060.90)/(1) - (64) = US$ 127.18
6-mo mortality (n of events)(USD 3048.50) - (USD 11060.90)/(0) - (1) = US$ 8012.40